Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
4DMedical Ltd ( (AU:4DX) ) has issued an update.
4DMedical Limited presented its achievements and future plans at the 2025 Annual General Meeting, highlighting a 95% increase in SaaS revenue and the successful launch of the CT:VQ solution, which received FDA clearance and its first commercial contract. The company reported a total income of $16.5 million for FY25 and maintained a strong cash balance of $33.5 million. With strategic investments in U.S. market initiatives and global industry conferences, 4DMedical is poised to capitalize on a large global market opportunity, particularly with its CT:VQ solution, which aims to improve patient care by reducing costs and enhancing access.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in advanced imaging and artificial intelligence to revolutionize respiratory care. The company offers a range of products, including the FDA-cleared XV Lung Ventilation Analysis Software and the CT:VQ solution, which provide functional and structural lung scans. These solutions are delivered through a Software-as-a-Service model, integrating seamlessly into existing hospital infrastructure to enhance physician productivity and patient care.
Average Trading Volume: 8,346,864
Technical Sentiment Signal: Buy
Current Market Cap: A$916.7M
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.